CONGRESS MATERIALS

Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
Shore N, Powles TB, Bedke J, Galsky MD, Kopyltsov E, Necchi A, Palou Redorta J, Vermette JJ, Randall AE, Pierce KJ, Cesari R, Steinberg GD June 4, 2022 ASCO 2022 Urothelial Cancer

A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B 

View Presentation View Abstract Plain Language Summary
Poster
Valderrama BP, Powles T, Sridhar SS, Caserta C, Loriot Y, Gupta S, Bellmunt J, Sternberg CN, Wang J, Costa N, Laliberte RJ, di Pietro A, Park SH, Grivas P June 4, 2022 ASCO 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to First-Line Chemotherapy

View Presentation View Abstract Plain Language Summary
Poster
Cortes JE,  Milojkovic D,  Gambacorti-Passerini C,  García-Gutiérrez V,  Mauro MJ,  Leip E, Purcell S,  Viqueira A,  Brümmendorf TH June 4, 2022 ASCO 2022 Hematology

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

View Presentation View Abstract Plain Language Summary
Poster
Jakubowiak A, Bahlis NJ, Raje NS, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM June 4, 2022 ASCO 2022 Hematology

Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy, for Patients with Relapsed or Refractory Multiple Myeloma: Results from MagnetisMM-1 

View Presentation View Abstract Plain Language Summary
Poster
Liu FX, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Thakkar S, Devgan G, Katzenstein H June 4, 2022 ASCO 2022 Urothelial Cancer

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The US Physician PARADIGM Study (part 2)

View Presentation
Poster
Bellmunt J, Powles T, Climent Duran MA, Sridhar SS, Gurney H, Costa N, di Pietro A, Huang B, Gupta S, Grivas P June 4, 2022 ASCO 2022 Urothelial Cancer

Long-Term Outcomes in Patients With Advanced Urothelial Carcinoma who Received Avelumab First-Line Maintenance With or Without Second-Line Treatment: Exploratory Analyses From JAVELIN Bladder 100

View Presentation View Abstract Plain Language Summary
Poster
Grosicki S,  Crafoord J, Koh Y, White D, Mellqvist U-H, Leip E, Kudla A, Finn G, Pruchniewski Ł June 4, 2022 ASCO 2022 Hematology

MagnetisMM-5: An Open-Label, Multicenter, Randomized Phase 3 Study of Elranatamab as Monotherapy and in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Fonseca R, Kuroda J, Ishida T, Popat R, Huang JSY, Yver A, Vandendries E, Elmeliegy M, Ma WD, Sborov DW June 4, 2022 ASCO 2022 Hematology

MagnetisMM-9: An Open-Label, Multicenter, Non-Randomized Phase 1/2 Study of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Oral Presentation
Finn RS, Rugo HS, Dieras V, Harbeck N, Im S-A, Gelmon KA, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Slamon DJ June 4, 2022 ASCO 2022 Breast Cancer

Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (ER+/HER2− ABC): Analyses From PALOMA-2

View Presentation View Abstract Plain Language Summary
Poster
Kopetz S, Bekaii-Saab T, Yoshino T, Chung C-H, Zhang X, Tabernero J June 4, 2022 ASCO 2022 Colorectal Cancer

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary